← Trials/Trial dossier/NCT00000177

CompletedPhase 3

Estrogen Hormone Protocol

Lead sponsor

National Institute on Aging (NIA)

Asset

estrogen

Listed sites

Recruiting sites

Enrollment

120

Study population

Alzheimer’s disease

Key I/E criterion

•Alzheimer's disease

Primary endpoint

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDIA0001

NCT IDNCT00000177

Timeline

Milestones

Study start1995-10 (month precision)

Primary completion1999-01actual (month precision)

Study completion1999-01actual (month precision)

Study first posted1999-11-01estimated

Last update posted2009-12-11estimated

Assets

Drug assets

estrogen

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age60 Years

SexFemale

Healthy volunteersNot accepted

Inclusion criteria

•Women with a diagnosis of Alzheimer's disease who currently are not taking estrogen replacement therapy, who have had a hysterectomy, and who are in stable general health

Exclusion criteria

•Patients with an uncontrolled health problem, such as untreated high blood pressure or thyroid disease.

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal LJ. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA. 2000 Feb 23;283(8):1007-15. doi: 10.1001/jama.283.8.1007.
PMID10697060via RESULT

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.